About Light Sciences Oncology

Light Sciences Oncology (LSO) is developing Aptocine™ (talaporfin sodium) for solid tumors as well as other indications such as BPH. Aptocine is a water-soluble drug targeted by a small, single-use, disposable drug activator included with the drug. Aptocine is designed to provide tolerable, effective, and repeatable treatments for patients. LSO has completed treatment of patients in a Phase 3 trial of Aptocine in hepatocellular carcinoma (HCC) and is currently enrolling patients in a Phase 3 trial for metastatic colorectal cancer (MCRC). LSO is also conducting clinical trials in benign prostatic hyperplasia (BPH), or enlargement of the prostate, and has clinical or preclinical programs in cardiovascular, ophthalmic, and dermatologic diseases. LSO’s development organization oversees engineering, clinical trials, manufacturing, and regulatory/legal affairs. The company has positioned Aptocine to benefit an increasing number of patients with a strong portfolio of intellectual property, innovative applications in development, and an exceptionally capable and efficient team.

Aptocine has three potential primary mechanisms of action: direct tumor cytotoxicity, apoptosis due to vascular shutdown, and anti-tumor immune stimulation. In clinical studies to date, there has been no evidence that Aptocine causes the serious toxicities associated with traditional cancer treatments.

Aptocine has been identified during development as Litx.